ArticleJournal of psychoactive drugs
Commercial Health Plan Coverage of Selected Treatments for Opioid Use Disorders from 2003 to 2014.
Article in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.Journal of substance use and addiction treatment · 2024Review
- Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.Annals of medicine · 2023Article
- Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.Health affairs (Project Hope) · 2023Article
- Buprenorphine Dispensing Among Youth Aged ≤19 Years in the United States: 2015-2020.Pediatrics · 2023Article
- Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder.Journal of general internal medicine · 2022Article
- Black clients in expansion states who used opioids were more likely to access medication for opioid use disorder after ACA implementation.Journal of substance abuse treatment · 2022Article
- The Role of the Pharmacist in Combating the Opioid Crisis: An Update.Substance abuse and rehabilitation · 2022Review
- Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.Journal of substance abuse treatment · 2021Article
- Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder.Medical care · 2021Article
- Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.Journal of substance abuse treatment · 2020Article
- Impact of the Young Adult Dependent Coverage Expansion on Opioid Overdoses and Deaths: a Quasi-Experimental Study.Journal of general internal medicine · 2020Article
- Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients.JAMA network open · 2020Article
- Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis.Health affairs (Project Hope) · 2020Article
- Article
- Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Review
- The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.Journal of substance abuse treatment · 2020Article
- Mental Health Parity and Addiction Equity Act and the Use of Outpatient Behavioral Health Services in the United States, 2005-2016.American journal of public health · 2019Article
- Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder.JAMA pediatrics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Opioid use disorders (OUDs) are receiving significant attention in the U.S. as a public health crisis. Access to treatment for OUDs is essential and was expected to improve following implementation of the federal parity law and the Affordable Care Act. This study examines changes in coverage and management of treatments for OUDs (opioid treatment programs (OTPs) as a covered service benefit, buprenorphine as a pharmacy benefit) before, during, and after parity and ACA implementation. Data are from three rounds of a nationally representative survey conducted with commercial health plans regarding behavioral health services in benefit years 2003, 2010, and 2014. Data were weighted to be representative of health plans' commercial products in the continental United States (2003 weighted N = 7,469, 83% response rate; 2010 N = 8,431, 89% response rate; and 2014 N = 6,974, 80% response rate). Results showed treatment for OUDs was covered by nearly all health plan products in each year of the survey, but the types and patterns varied by year. Prior authorization requirements for OTPs have decreased over time. Despite the promise of expanded access to OUD treatment suggested by parity and the ACA, improved health plan coverage for treatment of OUDs, while essential, is not sufficient to address the opioid crisis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.